Greater understanding and implementation of molecular biomarkers in non-small cell lung cancer (NSCLC) have led to improved patient outcomes. However, optimizing therapeutic strategies for patients with a molecular alteration continues to be challenging for the multidisciplinary team. Among these alterations, ROS1 rearrangements are rare, but have important clinical implications. Jonathan Dowell, MD, explores the significance of molecular alterations and ROS1 rearrangements in NSCLC. He also delves into the nuances and considerations of different targeted treatment options, patient characteristics, safety profiles of targeted therapies, and sequencing considerations to personalize treatment.
- Provider:Annenberg Center for Health Sciences At Eisenhower
- Activity Link: https://annenberg.net/courses/landingPage.php?courseID=61030
- Start Date: 2024-09-30 05:00:00
- End Date: 2024-09-30 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 147000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest